triumph 1 trial retatrutide ⭐️topline results from TRIUMPH-1, a Phase 3 clinical evaluating #retatrutide, an investigational GIP / GLP-1 / glucagon triple hormone receptor agonist, in adults with obesity or “overweight” What Pharmacists Need to Know

Second, the final maintenance dose may be lower than what you would use with retatrutide alone, because the cagrilintide component provides additional appetite suppression and metabolic benefit that reduces the need for maximum retatrutide dosing

doi: 10.1186/s12958-018-0323-4

GLP-1 agonists and other incretin mimetics have been generating a consistent flow of headlines in traditional media, occupying an increasing share of voice in social media, and spreading through word of mouth like wildfire across certain affluent social circles

Mechanisms of supralinear calcium integration in dendrites of hippocampal CA1 fast-spiking cells